of inherent limitations, detailed in our publication, cautious interpretation of the findings is suggested.In this context, use of estrogen-based therapies for prevention or treatment of postmenopausal depression in the general population, on the basis of our findings, was clearly not recommended. This option is precluded owing to known adverse effects of currently available hormone therapy regimens and uncertainties regarding appropriate combination of estrogens and progestogens in postmenopausal women with intact uterus. However, owing to its potential clinical implication, we considered of interest and accordingly highlighted, the 2-fold increased depression risk of women with premature ovarian insufficiency (menopause at <40 years). These women represent only 1% of the female population but comprise a high-risk group for additional postmenopausal diseases; therefore, they deserve to be appropriately followed up for early recognition and evaluation of depressive symptoms. Hormone therapy has been recommended for treatment of estrogen deficiency symptoms in this group, 5 albeit its effect on preventing depression should be explored following our findings. All in all, our meta-analysis points to novel research questions regarding the effect of the cumulative lifetime sex hormone exposure on nervous system and mental health and the sustained neuroprotective and antidepressive properties of estrogens or progesterone.